NHS Kingston
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.4 Other immunomodulating drugs > Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA462

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA462

1.1 Nivolumab is recommended, within its marketing authorisation, as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults after autologous stem cell transplant and treatment with brentuximab vedotin, when the company provides nivolumab in line with the commercial access agreement with NHS England.

https://www.nice.org.uk/guidance/ta462

Site by Devopa
© Copyright 2022 NHS. All rights reserved.